首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens
【24h】

Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens

机译:基于癌前列腺活检标本的STR型物质检测应用的决策分析模型

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The diagnostic algorithm for most cancers includes the assessment of a tissue specimen by a surgical pathologist, but if specimen provenance is uncertain, the diagnostic and therapeutic process carries significant risk to the patient. Over the last decade, short tandem repeat (STR) analysis has emerged as a DNA-based method with clinical applicability for specimen identity testing (also known as specimen provenance testing). Although the clinical utility of identity testing using STR-based analysis has been demonstrated in many studies, its economic value has not been established. Methods: We developed a decision-analytic model of the application of STR-based provenance testing of transrectal prostate biopsy specimens obtained as part of routine clinical care to rule out the presence of adenocarcinoma of the prostate, as compared with no STR-based testing. Using parameter values drawn from the published literature, the cost-effectiveness of STR-based testing was quantified by calculating the incremental cost-effectiveness ratio per quality-adjusted life-year gained. Results: In comparison to the current standard practice of no identity testing, identity testing by STR-based analysis has an incremental cost-effectiveness ratio of $65,570 per quality-adjusted life-year gained at a testing cost of $618 per person. At a cost of $515 per person, identity testing would meet the conservative standard of $50,000 per quality-adjusted life-year. At a test cost of $290 per person, identity testing would be cost saving. Conclusion: Given the rapidly declining pricing of STR-based identity testing, it is likely that testing to confirm the identity of positive prostate biopsy samples will be a cost-effective method for preventing treatment errors stemming from misidentification. Studies to formally establish the frequency of specimen provenance errors in routine clinical practice would therefore seem justified.
机译:背景:大多数癌症的诊断算法包括通过外科病理学家评估组织标本,但是,如果样品出现不确定,则诊断和治疗过程对患者的风险显着。在过去十年中,短串联重复(STR)分析作为基于DNA的方法,具有临床适用性,用于标本身份测试(也称为标本出处测试)。尽管在许多研究中已经证明了使用基于STR的分析的身份测试的临床效用,但其经济价值尚未建立。方法:制定了作为常规临床护理部分获得的脑前列腺活检标本的跨前列腺活检标本的应用的决策分析模型,以排除前列腺腺癌的存在,而没有基于基于STR的测试。使用从发布的文献中汲取的参数值,通过计算每个质量调整的救生年度的增量成本效益比量化了基于基于比率的测试的成本效益。结果:与目前没有身份测试的标准实践相比,基于STR的分析的身份测试具有每人618美元的测试费用的每年75,570美元的增量成本效益比率为65,570美元。每人515美元的费用,身份测试将符合每年调整50,000美元的保守标准。以每人290美元的测试成本,身份测试将节省成本。结论:鉴于基于STR型身份测试的定价迅速下降,测试阳性前列腺活检样品的身份可能是一种经济有效的方法,用于防止误识别的治疗误差。因此,研究常规地建立常规临床实践中标本的频率的频率似乎是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号